JAK Inhibition in Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- Other: JAK inhibitor treatment
- Registration Number
- NCT05456412
- Lead Sponsor
- Leiden University Medical Center
- Brief Summary
The treatment for Ulcerative Colitis (UC) aims to achieve and maintain remission and is usually lifelong and expensive. Current available medications are unable to break the cycle of chronic inflammation, and still a significant proportion of patients will fail to respond (primary non-response) or lose response over time (secondary non-response). There is now growing evidence that there is substantial interpatient variation in the composition of the inflammation associated network of immune cells. A deeper knowledge of the patient's alterations in the mucosal immune response would help identify key drivers of inflammation and select the appropriate therapy. By analyzing the changes in the composition of immune cells induced by Janus Kinase (JAK) inhibition, we aim to obtain a better insight into the mechanistic effects of JAK inhibition and the downstream effects. These mechanistic insights are needed to identifying potential responders and non-responders in the future.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Treatment JAK inhibitor JAK inhibitor treatment Clinical practice is followed for all patients treated with JAK inhibitor. Additional biopsies and blood is taken.
- Primary Outcome Measures
Name Time Method Multi-omics analyses of changes observed after JAK inhibition 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Leiden University Medical Center
🇳🇱Leiden, Zuid Holland, Netherlands